Lesaffre developed a new methodology to enumerate Bacillus spores using flow cytometry. This methodology can be used with Bacillus whether in food applications or dietary supplements.
Probiotics are gaining visibility; these micro-organisms accompany the growth of product dedicated to human health. Indeed, according to the FAO/WHO definition of a probiotic—“live microorganisms which when administered in adequate amounts confer a health benefit on the host”. Now, consumers are aware that probiotics may target other health benefits such as immunity. According a report from Supplemental Security Income (SSI), 82% of people know that probiotics can support immune health. To follow the growth of probiotics into food supplements and food matrices, spore probiotics are the solution.
Formulate with spores generates new challenges. Lesaffre offers the solution.
Indeed, respect of the product composition and specifications is mandatory for marketed preparations, especially the ones with probiotics and spore probiotics. The enumeration of spore probiotics is critical when a formulation contains them, whether in food applications or dietary supplements. Thanks to the Lesaffre methodology, this step is now facilitated.
A Lesaffre methodology suitable with LifeinU™ BSCU1
LifeinU™ BSCU1 is a stable probiotic that supports immune health. This Bacillus subtilis is eligible to a structure function claim in the US. The efficacy of this probiotic is supported by a clinical study and a new in-vitro scientific model: the intestine-on-chip.
As a spore probiotic, LifeinU™ BSCU1 has an excellent stability. that facilitate the formulation into long shelf-life application such as functional food and food supplements.
DISCOVER ALL OUR LATEST NEWS
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event dedicated to exploring the potential of probiotic yeasts. This live session brought together leading experts to present the latest scientific insights and real-world applications of live yeasts in human health.
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by Lesaffre, led by Jose Pinedo Rivera, Product Manager, had the opportunity to present MyCondro™ to an engaged audience of over 250 industry professionals. The session, titled “Keeping Pace with a Changing World: MyCondro™ Disrupts the Chondroitin Sulfate Market,” was well received, sparking interest and conversations around the future of joint health solutions.
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery Calcification: A Randomized, Placebo-Controlled Trial,” were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection, organized by the European Society of Hypertension (ESH), held in Milan in May 23–26, 2025.
